Dogwood Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Subsequent Events (Details)

Subsequent Events (Details)				1 Months Ended	3 Months Ended	9 Months Ended
Subsequent Events (Details)	Feb. 18, 2025 USD ($)	Oct. 09, 2024	Oct. 07, 2024 USD ($) $ / shares shares	Oct. 31, 2024 USD ($) shares	Sep. 30, 2024 USD ($) $ / shares shares	Sep. 30, 2024 USD ($) $ / shares shares	Sep. 29, 2024 shares	Dec. 31, 2023 $ / shares shares
Subsequent Event [Line Items]
Preferred stock, par value (in dollars per share) \| $ / shares					$ 0.0001	$ 0.0001		$ 0.0001
Number of Contingent Value Rights Issuable for each Common Share			1
Common stock outstanding (in shares)					1,110,317	1,110,317	27,757,937	770,317
Transaction costs \| $					$ 1,033,000	$ 1,033,000
Subsequent Events
Subsequent Event [Line Items]
Aggregate principal \| $			$ 19,500,000
Proceeds from loan \| $	$ 3,000,000		$ 16,500,000
Debt instrument basis spread on variable rate			2.00%
Debt instrument additional basis spread on variable rate			1.00
Stock split conversion ratio		0.04	0.04
Subsequent Events \| Amended and Restated 2020 Equity Incentive Plan
Subsequent Event [Line Items]
Shares authorized			2,278,233
Subsequent Events \| Amended and Restated 2020 Equity Incentive Plan \| Employee Director
Subsequent Event [Line Items]
Maximum aggregate number of shares			20,000
Subsequent Events \| Amended and Restated 2020 Equity Incentive Plan \| Non-employee Directors
Subsequent Event [Line Items]
Maximum aggregate number of shares			8,000
Subsequent Events \| Employee Stock Option
Subsequent Event [Line Items]
Accelerated vesting			116
Outstanding options issued			851
Subsequent Events \| Underwriter option
Subsequent Event [Line Items]
Transaction costs \| $				$ 1,155,000
Form S-1 Registration Statement \| Subsequent Events
Subsequent Event [Line Items]
Percentage Ownership Necessary To Request Filing With SEC			40.00%
Percentage Ownership Necessary To Request Filing With SEC, Single Holder			30.00%
Minimum Anticipated Aggregate Offering Price \| $			$ 10,000,000
Maximum Period For Filing Registration Statement After Request By Holders			60 days
Form S-3 Registration Statement \| Subsequent Events
Subsequent Event [Line Items]
Percentage Ownership Necessary To Request Filing With SEC			30.00%
Minimum Anticipated Aggregate Offering Price \| $			$ 7,500,000
Minimum Anticipated Aggregate Offering Price, Single Holder \| $			$ 1,000,000
Maximum Period For Filing Registration Statement After Request By Holders			30 days
Common stock \| Subsequent Events \| Underwriter option
Subsequent Event [Line Items]
Stock issued				10,568
Series A Preferred Stock \| Subsequent Events
Subsequent Event [Line Items]
Preferred stock dividend rate percentage			5.00%
Percentage of original shares remaining issued and outstanding			30.00%
Shares automatically converted			10,000
Series A Preferred Stock \| Subsequent Events \| Underwriter option
Subsequent Event [Line Items]
Stock issued				105.4190
Pharmagesic Holdings Inc. \| Subsequent Events
Subsequent Event [Line Items]
Percentage of shares acquired			100.00%
Maximum percentage issued			19.99%
Preferred stock, par value (in dollars per share) \| $ / shares			$ 0.0001
Number of shares of common issuable for each preferred share			10,000
Contingent Value Rights Agreement Term			7 years
Percentage of upfront payment to which holders are entitled			87.75%
Percentage ownership of outstanding rights that entitles holder to audit and enforcement			30.00%
Pharmagesic Holdings Inc. \| Common stock \| Subsequent Events
Subsequent Event [Line Items]
Number of shares issued			211,383
Pharmagesic Holdings Inc. \| Series A Preferred Stock \| Subsequent Events
Subsequent Event [Line Items]
Number of shares issued			2,108.3854